CVRx, Inc. CVRX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -92.94%
- 1 year
- -94.31%
5D -0.0118 (-1.73%)
- Market cap
- 14.27M
- Revenue (ttm)
- 47.26M
- Profit margin
- -123.75%
- EPS (ttm)
- -2.00
- Shares out
- 24.26M
- Forward P/E
- -5.84
- YTD return
- -92.94%
- 1-year return
- -94.31%
- 50-day average
- 12.92
- Volume
- 519.85K
- Avg volume
- 747.91K
- Open
- 0.5287
- Previous close
- 0.5329
- Day's range
- 0.4972 – 0.569
- 52-week range
- 0.4972 – 10.28
- Beta
- 1.11
- Analysts
- Buy
- Price target
- 18.17 (+3526.1%)
Key statistics
- 200-day average
- 11.61
- Enterprise value
- 244.11M
- Price / sales
- 6.42
- Price / book
- 4.64
- Revenue growth
- 27.20%
- Free cash flow
- -21.40M
- Total cash
- 100.16M
- Total debt
- 50.44M
- Return on equity
- -79.02%
- Short % of float
- 12.35%
Fundamental scorecard
8 of 25 checks passed on CVRX’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 23, 2025 | Dec 1, 2024 | -0.38 | — | — | — |
| Oct 29, 2024 | Sep 1, 2024 | -0.45 | -0.57 | -0.12 | -26.67% |
| Jul 29, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| Jul 29, 2024 | Jun 1, 2024 | -0.51 | -0.65 | -0.14 | -27.45% |
| Apr 30, 2024 | Mar 1, 2024 | -0.53 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.53 | -1.04 | -0.51 | -96.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2024 | Craig-Hallum | main | Buy | Buy |
| Oct 30, 2024 | Lake Street | main | Buy | Buy |
| Oct 30, 2024 | Canaccord Genuity | main | Buy | Buy |
| Oct 30, 2024 | Piper Sandler | reit | Overweight | Overweight |
| Oct 23, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cvrx.com
News
What's Next for CVRx, Inc. Shareholders After 59.76% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Robbins LLP Urges CVRX Shareholders Who Lost Money Investing in CVRx, Inc. to Contact the Firm for About Leading the Class Action
ROSEN, A LEADING LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX
CVRx ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against CVRx Inc. and Encourages Investors to Contact the Firm
What Does CVRx, Inc.'s 59.76% Stock Drop Mean for Investors? The Law Offices of Howard G.
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
DEADLINE ALERT for Arbor Realty Trust, Inc. (ABR), NVIDIA Corporation (NVDA), and CVRx, Inc. (CVRX): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (CVRX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm
CVRX DEADLINE: SueWallSt Reminds CVRx, Inc. Investors of Upcoming Securities Class Action Deadline
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in CVRx, Inc. of Class Action Lawsuit and Upcoming Deadlines - CVRX
Your note
Sign in to keep a note on CVRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEHBAHANI ALI | Director | Conversion of Exercise of derivative security | Dec 13, 2023 | 316 |
| GALLE LIZ | Officer | Conversion of Exercise of derivative security | Oct 15, 2023 | 778 |
| HYKES KEVIN | Chief Executive Officer | Purchase | Aug 4, 2024 | 30,000 |
| JOHNSON & JOHNSON INNOVATION - JJDC, INC. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 28, 2024 | 0 |
| OASHEIM JARED | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 17, 2023 | 15,447 |
| PALMER CRAIG E | Officer | Conversion of Exercise of derivative security | Mar 24, 2024 | 1,229 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 16.91% | 4,103,430 | 51.29M | Sep 29, 2024 |
| NEA Management Company, LLC | 9.77% | 2,370,542 | 29.63M | Sep 29, 2024 |
| Blackrock Inc. | 3.75% | 909,423 | 11.37M | Sep 29, 2024 |
| Vanguard Group Inc | 3.40% | 824,290 | 10.30M | Sep 29, 2024 |
| Parkman Healthcare Partners LLC | 2.81% | 682,897 | 8.54M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 2.25% | 545,300 | 6.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.24% | 544,348 | 6.80M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.40% | 338,536 | 4.23M | Oct 30, 2024 |
| College Retirement Equities Fund-Stock Account | 0.69% | 167,840 | 2.10M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.68% | 165,802 | 2.07M | Sep 29, 2024 |
| Trust for Professional Managers-Mairs & Power Small Cap Fund | 0.59% | 142,456 | 1.78M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 136,885 | 1.71M | Aug 30, 2024 |
